T

Thor Medical ASA
OSE:TRMED

Watchlist Manager
Thor Medical ASA
OSE:TRMED
Watchlist
Price: 2.835 NOK 10.74% Market Closed
Market Cap: 665.8m NOK
Have any thoughts about
Thor Medical ASA?
Write Note

Thor Medical ASA
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Thor Medical ASA
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
T
Thor Medical ASA
OSE:TRMED
Additional Paid In Capital
kr61.5m
CAGR 3-Years
-51%
CAGR 5-Years
-40%
CAGR 10-Years
-6%
Hofseth Biocare ASA
OSE:HBC
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bergenbio ASA
OSE:BGBIO
Additional Paid In Capital
kr8.8m
CAGR 3-Years
-72%
CAGR 5-Years
-49%
CAGR 10-Years
N/A
L
Lytix Biopharma AS
OSE:LYTIX
Additional Paid In Capital
kr47.3m
CAGR 3-Years
40%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Additional Paid In Capital
kr265.8m
CAGR 3-Years
1%
CAGR 5-Years
12%
CAGR 10-Years
8%
N
Nykode Therapeutics ASA
OSE:NYKD
Additional Paid In Capital
$129m
CAGR 3-Years
28%
CAGR 5-Years
17%
CAGR 10-Years
N/A
No Stocks Found

Thor Medical ASA
Glance View

Market Cap
665.8m NOK
Industry
Biotechnology

Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The company is headquartered in Oslo, Oslo and currently employs 16 full-time employees. The company went IPO on 2014-07-07. The firm is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The firm is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.

TRMED Intrinsic Value
0.124 NOK
Overvaluation 96%
Intrinsic Value
Price
T

See Also

What is Thor Medical ASA's Additional Paid In Capital?
Additional Paid In Capital
61.5m NOK

Based on the financial report for Jun 30, 2024, Thor Medical ASA's Additional Paid In Capital amounts to 61.5m NOK.

What is Thor Medical ASA's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
-6%

Over the last year, the Additional Paid In Capital growth was 8 686%. The average annual Additional Paid In Capital growth rates for Thor Medical ASA have been -51% over the past three years , -40% over the past five years , and -6% over the past ten years .

Back to Top